Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Buys Thermo Fisher Mass Specs for Services Business

NEW YORK (GenomeWeb News) – Quebec, Canada-based Warnex said today that its Bioanalytical Services division has purchased two TSQ Vantage mass spectrometers from Thermo Fisher Scientific, which it will use in its drug research services offerings.
Warnex President and CEO Mark Busgang said in a statement that the firm is the first clinical research organization in Canada to acquire the new TSQ Vantage system. “The increased sensitivity of this new generation of systems will allow us to detect our customers’ compounds at very low quantitation levels with great precision,” he said.
Warnex said that the TSQ Vantage system provides 10 times more sensitivity than other triple quadrupole instruments on the market.
Terms of the purchase were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.